These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

163 related items for PubMed ID: 6124428

  • 1. Dopamine autoreceptor and postsynaptic receptor blocking potency of neuroleptics.
    Kendler KS, Bracha HS, Davis KL.
    Eur J Pharmacol; 1982 Apr 23; 79(3-4):217-23. PubMed ID: 6124428
    [Abstract] [Full Text] [Related]

  • 2. Chronic autoreceptor blockade and neuroleptic-induced dopamine receptor hypersensitivity.
    Gordon JH, Clopton JK, Curtin JC, Koller WC.
    Pharmacol Biochem Behav; 1987 Feb 23; 26(2):223-8. PubMed ID: 3575347
    [Abstract] [Full Text] [Related]

  • 3. Neuroleptic-induced catalepsy: a D2 blockade phenomenon?
    Klemm WR.
    Pharmacol Biochem Behav; 1985 Dec 23; 23(6):911-5. PubMed ID: 2867564
    [Abstract] [Full Text] [Related]

  • 4. The effects of some atypical neuroleptics on apomorphine-induced behaviors as a measure of their relative potencies in blocking presynaptic versus postsynaptic dopamine receptors.
    Robertson A, MacDonald C.
    Pharmacol Biochem Behav; 1986 Jun 23; 24(6):1639-43. PubMed ID: 2874567
    [Abstract] [Full Text] [Related]

  • 5. Involvement of different dopamine receptors in rat diphasic motility response to apomorphine.
    Vaccheri A, Dall'Olio R, Gandolfi O, Montanaro N.
    Psychopharmacology (Berl); 1986 Jun 23; 89(3):265-8. PubMed ID: 2873607
    [Abstract] [Full Text] [Related]

  • 6. Differences in the time course of dopaminergic supersensitivity following chronic administration of haloperidol, molindone, or sulpiride.
    Prosser ES, Pruthi R, Csernansky JG.
    Psychopharmacology (Berl); 1989 Jun 23; 99(1):109-16. PubMed ID: 2506596
    [Abstract] [Full Text] [Related]

  • 7. 3-Methoxytyramine accumulation: effects of typical neuroleptics and various atypical compounds.
    Saller CF, Salama AI.
    Naunyn Schmiedebergs Arch Pharmacol; 1986 Oct 23; 334(2):125-32. PubMed ID: 2878374
    [Abstract] [Full Text] [Related]

  • 8. Effects of DA-1- and DA-2-dopamine antagonists on apomorphine-induced inhibition of peripheral sympathetic neurotransmission.
    Hietala J.
    J Auton Pharmacol; 1988 Dec 23; 8(4):297-302. PubMed ID: 2855331
    [Abstract] [Full Text] [Related]

  • 9. Changes in sensitivity of release modulating dopamine autoreceptors after chronic treatment with haloperidol.
    Nowak JZ, Arbilla S, Galzin AM, Langer SZ.
    J Pharmacol Exp Ther; 1983 Aug 23; 226(2):558-64. PubMed ID: 6875865
    [Abstract] [Full Text] [Related]

  • 10. Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity.
    Perrault G, Depoortere R, Morel E, Sanger DJ, Scatton B.
    J Pharmacol Exp Ther; 1997 Jan 23; 280(1):73-82. PubMed ID: 8996184
    [Abstract] [Full Text] [Related]

  • 11. Antagonism of bromocriptine-induced cage climbing behaviour in mice by the selective D-2 dopamine receptor antagonists, metoclopramide and molindone.
    Balsara JJ, Nandal NV, Gada VP, Bapat TR, Chandorkar AG.
    Indian J Physiol Pharmacol; 1986 Jan 23; 30(1):85-90. PubMed ID: 2950056
    [Abstract] [Full Text] [Related]

  • 12. SCH 23390, a selective dopamine D1 antagonist, activates dopamine neurons but fails to prevent their inhibition by apomorphine.
    Mereu G, Collu M, Ongini E, Biggio G, Gessa GL.
    Eur J Pharmacol; 1985 May 20; 111(3):393-6. PubMed ID: 3894035
    [Abstract] [Full Text] [Related]

  • 13. Alterations in peripheral and central dopamine receptor sensitivity after subchronic treatment with fluphenazine and sulpiride.
    Hietala J, MacDonald E, Syvälahti E, Scheinin M.
    Pharmacol Toxicol; 1987 Jul 20; 61(1):48-52. PubMed ID: 3628181
    [Abstract] [Full Text] [Related]

  • 14. Dopamine D-2 antagonists reverse apomorphine-induced decreased water intake in the rat: prediction of antipsychotic drugs with few extrapyramidal side-effects?
    Ljungberg T.
    J Neural Transm; 1989 Jul 20; 76(2):79-90. PubMed ID: 2565360
    [Abstract] [Full Text] [Related]

  • 15. Atypical neuroleptics suppress dopaminergic behavioral supersensitivity.
    Schremmer C, Morgenstern R, Fink H, Ott T.
    Psychopharmacology (Berl); 1990 Jul 20; 100(3):399-403. PubMed ID: 1969173
    [Abstract] [Full Text] [Related]

  • 16. Blockade of the dopamine depressor response by molindone, a newly introduced neuroleptic.
    Nandal NV, Mane VR, Balsara JJ, Chandorkar AG.
    Indian J Physiol Pharmacol; 1980 Jul 20; 24(2):143-7. PubMed ID: 6103868
    [Abstract] [Full Text] [Related]

  • 17. Antipsychotic substances and dopamine in the rat brain; behavioral studies reveal distinct dopamine receptor systems.
    Van Ree JM, Elands J, Király I, Wolterink G.
    Eur J Pharmacol; 1989 Aug 03; 166(3):441-52. PubMed ID: 2572429
    [Abstract] [Full Text] [Related]

  • 18. Drug effects on pre- and postsynaptic dopamine receptors.
    Andén NE, Grabowska-Andén M.
    Adv Biochem Psychopharmacol; 1980 Aug 03; 24():57-64. PubMed ID: 6105802
    [No Abstract] [Full Text] [Related]

  • 19. Differential effects of dopamine receptor antagonists on the sexual behavior of male rats.
    Pfaus JG, Phillips AG.
    Psychopharmacology (Berl); 1989 Aug 03; 98(3):363-8. PubMed ID: 2568656
    [Abstract] [Full Text] [Related]

  • 20. Climbing behaviour induced by apomorphine in mice: a potential model for the detection of neuroleptic activity.
    Costall B, Naylor RJ, Nohria V.
    Eur J Pharmacol; 1978 Jul 01; 50(1):39-50. PubMed ID: 28233
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.